2. Potential effect modifiers.
| Study name | Intervention 1 | Intervention 2 | Primary transplantation | Reason for transplantation: hepatitis C virus | Reason for transplantation: hepatitis B virus | Reason for transplantation: alcoholic cirrhosis | Reason for transplantation: other reasons | Years of randomisation | Additional drug used for induction | Average follow‐up in months | Risk of bias |
| Belli 1998 | Cyclosporine A plus glucocorticosteroids | Cyclosporine A | 104/104 (100.0%) | 42/104 (40.4%) | 24/104 (23.1%) | 9/104 (8.7%) | 21/104 (20.2%) | 1991 to 1995 | Yes | 41 | High |
| Pageaux 2004 | Cyclosporine A plus glucocorticosteroids | Cyclosporine A | 174/174 (100.0%) | 26/174 (14.9%) | 12/174 (6.9%) | 84/174 (48.3%) | 52/174 (29.9%) | 1999 to 2001 | Yes | 6 | High |
| Masetti 2010 | Everolimus | Cyclosporine A | 78/78 (100.0%) | Not stated | Not stated | Not stated | Not stated | 2006 to 2008 | Yes | 22 | High |
| Sterneck 2000 | Cyclosporine A plus mycophenolate plus glucocorticosteroids | Cyclosporine A plus azathioprine plus glucocorticosteroids | 57/57 (100.0%) | Not stated | Not stated | Not stated | Not stated | 1996 to 1998 | No | 6 | High |
| De Simone 2012 | Tacrolimus plus everolimus | Intervention 1: Everolimus Intervention 2: Tacrolimus |
719/719 (100.0%) | 175/719 (24.3%) | 49/719 (6.8%) | 171/719 (23.8%) | 258/719 (35.9%) | 2008 to 2011 | Yes | 36 | High |
| Baiocchi 2006 | Cyclosporine A | Tacrolimus | 20/20 (100.0%) | 8/20 (40.0%) | 4/20 (20.0%) | 3/20 (15.0%) | 1/20 (5.0%) | Not stated | No | 3 | High |
| Cholongitas 2011 | Cyclosporine A | Tacrolimus | 66/66 (100.0%) | Not stated | Not stated | Not stated | Not stated | 1996 to 1997 | No | 97 | High |
| Fernandez‐Miranda 1998 | Cyclosporine A | Tacrolimus | Not stated | Not stated | Not stated | Not stated | Not stated | 1993 to 1995 | Yes | 22 | High |
| Fung 1991 | Cyclosporine A | Tacrolimus | 81/81 (100.0%) | Not stated | 0/81 (0.0%) | Not stated | Not stated | 1990 | Yes | 12 | High |
| Greig 2003 | Cyclosporine A | Tacrolimus | 139/143 (97.2%) | 47/143 (32.9%) | 0/143 (0.0%) | 25/143 (17.5%) | 67/143 (46.9%) | 1996 | Yes | 12 | High |
| Loinaz 2001 | Cyclosporine A | Tacrolimus | 100/100 (100.0%) | Not stated | Not stated | Not stated | Not stated | Not stated | Yes | 24 | High |
| O'Grady 2002 | Cyclosporine A | Tacrolimus | 606/606 (100.0%) | 60/606 (9.9%) | 20/606 (3.3%) | 110/606 (18.2%) | 98/606 (16.2%) | 1997 to 1999 | Yes | 36 | High |
| Shenoy 2008 | Cyclosporine A | Tacrolimus | Not stated | 32/60 (53.3%) | 5/60 (8.3%) | 8/60 (13.3%) | 16/60 (26.7%) | 2002 to 2004 | Yes | 12 | High |
| Stegall 1997 | Cyclosporine A | Tacrolimus | Not stated | Not stated | 0/71 (0.0%) | Not stated | Not stated | Not stated | Yes | 6 | High |
| Zervos 1998 | Cyclosporine A | Tacrolimus | Not stated | 49/49 (100.0%) | 0/49 (0.0%) | 0/49 (0.0%) | 0/49 (0.0%) | 1995 to 1996 | Yes | 14 | High |
| Chen 2002 | Cyclosporine A plus azathioprine | Tacrolimus | 81/81 (100.0%) | 2/81 (2.5%) | 2/81 (2.5%) | 6/81 (7.4%) | 71/81 (87.7%) | 1990 to 1992 | No | 124 | High |
| Jonas 2005 | Cyclosporine A plus azathioprine | Tacrolimus | 121/121 (100.0%) | 35/121 (28.9%) | 30/121 (24.8%) | 20/121 (16.5%) | 37/121 (30.6%) | 1990 to 1992 | Yes | 144 | High |
| Manousou 2014 | Tacrolimus plus azathioprine | Tacrolimus | 97/97 (100.0%) | 97/97 (100.0%) | 0/97 (0.0%) | 0/97 (0.0%) | 0/97 (0.0%) | 2000 to 2007 | Yes | 96 | High |
| Boudjema 2011 | Tacrolimus plus mycophenolate plus glucocorticosteroids | Tacrolimus | 195/195 (100.0%) | 16/195 (8.2%) | 4/195 (2.1%) | 83/195 (42.6%) | 91/195 (46.7%) | 2003 to 2007 | Yes | 11 | High |
| Asrani 2014 | Tacrolimus plus sirolimus | Tacrolimus | 222/222 (100.0%) | 72/222 (32.4%) | 30/222 (13.5%) | 79/222 (35.6%) | 40/222 (18.0%) | 2000 to 2003 | Yes | 24 | High |
| Pham 1998 | Cyclosporine A plus azathioprine plus glucocorticosteroids | Tacrolimus plus glucocorticosteroids | 76/76 (100.0%) | Not stated | Not stated | Not stated | Not stated | 1990 to 1992 | No | 27 | High |
| Porayko 1994 | Cyclosporine A plus azathioprine plus glucocorticosteroids | Tacrolimus plus glucocorticosteroids | 37/37 (100.0%) | Not stated | Not stated | 6/37 (16.2%) | 29/37 (78.4%) | 1990 to 1991 | No | 12 | High |
| Martin 2004 | Cyclosporine A plus glucocorticosteroids | Tacrolimus plus glucocorticosteroids | 79/79 (100.0%) | 79/79 (100.0%) | 0/79 (0.0%) | 0/79 (0.0%) | 0/79 (0.0%) | Not stated | Yes | 12 | High |
| Jain 2001 | Tacrolimus plus mycophenolate plus glucocorticosteroids | Tacrolimus plus glucocorticosteroids | 350/350 (100.0%) | 95/350 (27.1%) | 15/350 (4.3%) | 70/350 (20.0%) | 160/350 (45.7%) | 1995 to 1998 | No | 34 | High |
| Fisher 1998 | Cyclosporine A plus mycophenolate | Tacrolimus plus mycophenolate | 99/99 (100.0%) | 37/99 (37.4%) | 7/99 (7.1%) | 11/99 (11.1%) | 44/99 (44.4%) | 1995 to 1997 | Yes | 48 | High |
| Pelletier 2013 | Tacrolimus plus mycophenolate plus glucocorticosteroids | Tacrolimus plus mycophenolate | 100/100 (100.0%) | 54/100 (54.0%) | Not stated | 42/100 (42.0%) | 8/100 (8.0%) | 2002 to 2005 | No | 69 | High |